Neuropathix, Inc.
20.7.2021 15:01:52 CEST | ACCESS Newswire | Press release
DOYLESTOWN, PA / ACCESSWIRE / July 20, 2021 / Neuropathix, Inc. ("Neuropathix" or the "Company") (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication of the global Patent Cooperation Treaty (PCT) Patent under Publication No. WO/2021/097351 "Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders."
One of the compounds disclosed as part of this PCT Patent is the Company's proprietary ingredient LEA™. LEA™ is the trademark and acronym for Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine, the designated International Nomenclature Cosmetic Ingredient (INCI) name assigned by Personal Care Products Council (PCPC) for the Company's patented monotherapeutic compound.
"A few years ago we were asked if we had a compound to treat radiation dermatitis, a significant problem for patients undergoing chemotherapy and radiation treatments for breast cancer. Of the CBD analogues that we developed, we felt that LEA™ was best to test in parallel with cannabidiol and tacrolimus. The preclinical results were very promising and brought us to not only patenting these select compounds, but also formulating a cream which we believe may be useful for relief of symptoms across several disorders. We are now looking at launching two branded products containing LEA™, which we currently expect will happen sometime between the first and second quarter of 2022," said Dean Petkanas, CEO of Neuropathix.
LEA™, the Company's novel small molecule has been shown in preclinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin cells irradiated with UVB-radiation were used in testing to monitor the comparison of the two substances. Although both compounds were effective in preventing the release of TNF-alpha (TNFα), only LEA™ was found to be effective in preventing the release of IL-1-beta (IL-1β) from human epidermal cells. The experiments completed to date suggest that LEA™ may be more effective than cannabidiol ("CBD") in preventing inflammatory responses relevant to UVB-radiation.
Additionally, LEA™ was shown in preclinical testing to decrease inflammatory cytokine (TNFα, IL-1β, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. LEA™ was shown to be effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts cells. IL-6 is a cytokine (an immune system signaling molecule) that has been shown to promote inflammation and is currently among the targets believed to be creating the cytokine storm in SARS-CoV-2 ("COVID-19").
The market demand for products that defend against harmful UVB and UVA radiation has surged in recent years. Sun care products have moved from solely being intended for skin care to being a multifunctional first line of defense to sun exposure. The global sun care market has witnessed significant growth and is projected to reach $24.9 billion USD by 2024, while the global skin care products market is projected to reach $183.03 billion USD by 2025.
About Neuropathix, Inc.
Neuropathix is a biopharmaceutical company focused on the research and development of a pipeline of next generation, socially responsible pain management and neuroprotective therapeutics to treat patients with significant unmet medical needs. Over the past ten years, Neuropathix has discovered, developed, and patented a global intellectual property estate, led by its lead clinical target, KLS-13019, as novel, new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. The Company's family of patented monotherapeutic molecules focuses on treating oxidative stress-related diseases, chronic pain management, and neurodegenerative disorders. The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports. Neuropathix conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Neuropathix, visit www.neuropathix.com and the Company's Twitter page at @neuropathix.
Forward-Looking Statements
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, including, without limitation, the Company's business plan, plan of operations, the viability of the Company's drug candidates, the targeted beneficial effects of LEA™, the sun care and skin care markets, the Company's position, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Media Relations:
Thoma Kikis
Chief Communications Officer
P: 917-652-2479
E: thoma@neuropathix.com
www.neuropathix.com
Investor Relations:
Louie Toma
Managing Director
CORE IR
P: 516-222-2560
E: louie@coreir.com
www.coreir.com
SOURCE: Neuropathix, Inc.
View source version on accesswire.com:
https://www.accesswire.com/655929/Neuropathix-Inc-Announces-Publication-of-PCT-Patent-Application-for-the-Treatment-of-Radiation-Dermatitis-and-Other-Skin-Disorders
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Names Charlie Harte Director of Field Sales & Recruiting - Canada12.10.2026 16:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Charlie Harte joins Chervon as Director of Field Sales and Recruiting - Canada, effective Monday, October 12, 2026, reporting to Neil Harrison, VP/MD Sales and Marketing - Canada. Harte brings 15+ years of experience in the Canadian power tools, outdoor power equipment, and hand tool market. Additionally, he has 6+ years of experience selling into the commercial plumbing arena. Early in his career, Harte spent six years at Black and Decker growing into the National Sales and Marketing Manager position for B&D Canada. He subsequently became Director of Sales for Irwin Industrial Tools and then became a Director of Sales for Milwaukee Canada. Harte moved into the VP Sales position for Uponor Advanced Plumbing Solutions. Harte has an impressive track record in field sales leadership and strategic account development. He is known for his ability to build and manage high-performance sales teams throughout Canada. "Charlie brings an outst
Chervon Names Thomas G. Kentouris Vice President of Field Sales12.10.2026 15:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Thomas G. Kentouris joins Chervon as Vice President of Field Sales, effective Monday, October 12, 2026, reporting to Matt DeFeo, SVP of Sales Training and Recruiting. Kentouris brings 14+ years of Power Tool and Outdoor Power Equipment experience at TTI. His career began as a sales rep and advanced through a series of increasingly responsible positions, culminating in SVP of Field Sales for Eastern U.S.A. Kentouris delivered exceptional sales growth results year after year in his areas of responsibility. His ability to develop store-level partnerships and store-level sell-through programs all resulted in exceptional levels of success. Kentouris distinguished himself as an outstanding recruiting talent as he and his teams were responsible for recruiting over 2,000 high potential recent college graduates into the TTI system. Kentouris did an amazing job mentoring, developing, and promoting hundreds of his people into higher level posi
Chervon Names Randall Durkan Vice President of Supply Chain - North America12.10.2026 15:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Randy Durkan joins Chervon as Vice President of Supply Chain - North America, effective Monday, October 12, 2026, reporting to CEO Joe Galli. Randy Durkan brings over 25 years of supply chain management experience, including extensive leadership in power tools, hand tools, and outdoor power equipment. He has proven experience building high-performance supply chain teams and has consistently delivered outstanding service levels, inventory optimization, and cost-reduction results. Durkan is known for developing strong supply chain partnerships with key customers, driving cross-functional collaboration, and deploying technology to achieve world-class supply chain performance. He began his early supply chain career in Bentonville, Arkansas, supporting Walmart-focused collaboration across several consumer goods companies. His work at Vi-Jon contributed to Walmart's 2008 Supplier of the Year Award. Durkan then spent six years in supply ch
Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 20269.10.2026 17:00:00 CEST | Press release
MIAMI, FL / ACCESS Newswire / October 9, 2026 / Miami Fashion Week® (MIAFW) celebrates its 10th anniversary this year, returning October 13-18, 2026 featuring industry programming, runway shows, and special events bringing together international designers, Latin American talent and Miami's creative community. For a decade, MIAFW has served as a bridge between Miami and the international fashion industry, creating a platform for designers while expanding beyond the runway through sustainability, technology, education and cultural exchange. The milestone edition brings together international designers, Latin American talent, fashion innovation and a new Stitch Lab retail experience Throughout these ten years, MIAFW has pioneered initiatives at the intersection of fashion, sustainability and technology. Founded in 2017, the MIAFW Summit created a space for dialogue and education around the industry's evolving challenges and opportunities. Building on that vision, the Virtual Fashion Award
IROS 2026|PaXini Showcases Full-Stack Tactile Strategy for Physical AI8.10.2026 18:15:00 CEST | Press release
PITTSBURGH, PA / ACCESS Newswire / October 8, 2026 / As global researchers and industry leaders gathered in Pittsburgh for IROS 2026 (Sep. 27-Oct. 1) to tackle the scaling of Physical AI, PaXini AI took center stage, showcasing its full-stack products from chips to humanoid robots and hosting GEEN 2026 · IROS, the Global Embodied Ecosystem Night. The event was not merely an exchange, but an industry gathering focused on the deployment of embodied intelligence. As a leader in tactile sensing, PaXini has built a full-stack closed loop centered on touch: PIE - Perception, Intelligence, Execution. Perception enables robots to understand the real environment more comprehensively and accurately. Intelligence uses data and experience to move robots from being programmed to adapting and generalizing. Execution, through powerful actuators and dexterous end-effectors, allows robots to complete complex tasks. These three layers drive one another and form PaXini's infrastructure capability for the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom